This content is machine translated Corona pandemic Current data on COVID-19 and diabetes In particular, older diabetics with a high BMI have an increased risk of a severe course and mortality rates are also higher compared to the general population. The interactions involved…
View Post 5 min This content is machine translated Diabetic nephropathy Gliflozines may slow progression of renal failure Nephropathy as a late complication of diabetes is a common cause of renal failure requiring dialysis. In the CREDENCE trial, SGLT-2 inhibitors slowed the progression of renal dysfunction in diabetic…
View Post 7 min This content is machine translated Atrial fibrillation In practice more and more often Atrial fibrillation is increasing significantly in frequency. However, the symptoms are often not very specific. Therefore, special attention should be paid to risk factors such as hypertension, obesity, and physical…
View Post 4 min This content is machine translated Behçet's disease Apremilast approved for the treatment of oral aphthae Behçet’s disease is a rare, chronic, multisystemic inflammatory disease that causes vasculitis. Oral aphthae occur in more than 97% of affected individuals and are associated with significant impairment of quality…
View Post 3 min This content is machine translated Cancer medicine of the future Car-T cell therapy and its application in practice CAR-T cell technology is considered the latest achievement in cancer medicine. The first approvals in Europe took place in mid-2018 – Switzerland followed at the end of 2018. Currently, the…
View Post 4 min This content is machine translated SGLT-2 inhibitors Dapagliflozin now also available for non-diabetics for the treatment of heart failure (HFrEF) Based on the results of the DAPA-HF study, Swissmedic has approved dapagliflozin for the treatment of heart failure with reduced ejection fraction (HFrEF), whether or not patients have type 2…
View Post 4 min This content is machine translated Guselkumab Study success: application for admission to PsoA submitted New Phase III data from the DISCOVER-1 and DISCOVER-2 studies show improvement in joint and skin symptoms of psoriatic arthritis at week 52, and an indication expansion of guselkumab is…
View Post 5 min This content is machine translated Non-resectable BRAF-mutated melanoma Update COLUMBUS study: BRAF/MEK inhibition has long-lasting effect For almost two years, an effective therapeutic option has been available for patients with non-resectable or metastatic BRAFV600-mutated melanoma with the combination of encorafenib plus binimetinib. An analysis of the…
View Post 2 min This content is machine translated VERTIS-CV Study Evidence base of SGLT-2 inhibitors supplemented by further piece of the mosaic Ertugliflozin as an add-on to standard treatment was shown to be non-inferior to placebo in terms of MACE (major adverse cardiac event) in this large-scale international study. This confirmed the…
View Post 5 min This content is machine translated Therapy of overactive bladder Minimize side effect risks and increase compliance Anticholinergics are among the standard pharmacological therapies for overactive bladder. It is important to choose the right preparation for each patient. The side effect risks vary considerably in some cases.…
View Post 2 min This content is machine translated Influenza virus A and B Do not miss flu vaccination During the current COVID-19 pandemic, inpatient health care services could be severely strained as the number of cases increases. Flu vaccination can help reduce the burden of illness in winter…
